About: NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.49 (+3.75%)
NRXP NASDAQ NRX Pharmaceuticals Inc
NRX Pharmaceuticals Inc share price
NRXP price activity
Last Price
$2.490
Change (24hr)
0.09 USD (3.75%)
Volume
809.51K
Volume (4w avg)
-
Open
$2.36
Day Range
$2.24 - $2.50
Previous Close
$2.40
Last Trade
23 Oct, 8:00 pm GMT+0
Delayed
23 Oct, 8:00 pm GMT+0
NRXP price performance
Delayed
23 Oct, 8:00 pm GMT+0
NRXP Market Signals